Diabetes HbA1c control at 8.0% is a key concern for anyone managing type 2 diabetes, whether through an NHS review, occupational health assessment, or a Passport Health Plan evaluation. An HbA1c of 8.0% (64 mmol/mol) sits above the targets recommended by NICE and NHS guidance for most adults, signalling that blood glucose management may need to be reviewed. This article explains what this result means clinically, how UK guidelines apply, what steps can help lower your HbA1c, and when to seek further assessment or specialist referral from your GP or diabetes team.

What an HbA1c of 8.0% Means for Your Diabetes Management

An HbA1c of 8.0% (64 mmol/mol) indicates blood glucose has been running above optimal levels for two to three months, exceeding NHS and Diabetes UK targets for most adults with type 2 diabetes and warranting a management review.

Have any more questions about this? Message our pharmaceutical team to get more info →

HbA1c — glycated haemoglobin — is a blood test that reflects your average blood glucose levels over the preceding two to three months. It is expressed either as a percentage or in millimoles per mole (mmol/mol). An HbA1c of 8.0% equates to approximately 64 mmol/mol, which sits above the targets recommended for most adults with type 2 diabetes in the UK (NHS; Diabetes UK).

An HbA1c at this level indicates that blood glucose has been running higher than optimal over a sustained period. While it does not constitute an emergency, it does signal that current management — whether through lifestyle measures, medication, or both — may need to be reviewed. Persistently elevated HbA1c is associated with an increased risk of long-term diabetes complications, including:

• Cardiovascular disease (heart attack and stroke)

• Diabetic retinopathy (damage to the retina)

• Peripheral neuropathy (nerve damage, particularly in the feet)

• Chronic kidney disease (diabetic nephropathy)

It is important to understand that HbA1c is not a standalone measure of health, and the test has recognised limitations. Results may be unreliable in people with certain haemoglobin variants or haemoglobinopathies (such as sickle cell trait), haemolytic or iron-deficiency anaemia, chronic kidney disease, recent blood transfusion, or during pregnancy. In these circumstances, alternative measures of glycaemic control — such as fructosamine, capillary blood glucose monitoring, or continuous glucose monitoring (CGM) — may be more appropriate. Your GP or diabetes team can advise on which measure is most suitable for you.

Individual HbA1c targets may also vary depending on age, duration of diabetes, presence of other conditions, and risk of hypoglycaemia. A result of 8.0% in one person may carry different clinical implications than in another. For the majority of people with type 2 diabetes, however, this level warrants a structured review of the current management plan with a healthcare professional.

NHS and NICE Guidance on HbA1c Targets in Type 2 Diabetes

NICE NG28 recommends an HbA1c target of 48 mmol/mol (6.5%) for most adults with type 2 diabetes, rising to 53 mmol/mol (7.0%) where hypoglycaemia risk applies, with treatment intensification advised if levels persistently reach 58 mmol/mol (7.5%).

The National Institute for Health and Care Excellence (NICE) provides clear guidance on HbA1c targets for adults with type 2 diabetes in guideline NG28. According to NICE, the recommended HbA1c target for most adults with type 2 diabetes managed with lifestyle changes or a single non-hypoglycaemic drug (such as metformin) is 48 mmol/mol (6.5%). For those on medications that carry a risk of hypoglycaemia, or where a more relaxed target is clinically appropriate, the recommended level is 53 mmol/mol (7.0%).

NICE acknowledges that individualised targets are sometimes appropriate and advises that these should be agreed through shared decision-making between the person and their clinical team, weighing the potential benefits of tighter control against risks such as hypoglycaemia, treatment burden, and individual circumstances. Importantly, NICE does not specify a fixed numeric upper limit for a relaxed target; rather, it emphasises that any relaxation should be an active, documented clinical decision rather than a default outcome of suboptimal control. NICE also advises that treatment should be intensified if HbA1c persistently reaches or exceeds 58 mmol/mol (7.5%), unless this is clinically inappropriate.

The NHS National Diabetes Audit defines eight core annual care processes recommended for people living with diabetes in England. These are: HbA1c measurement, blood pressure, serum cholesterol, serum creatinine and estimated glomerular filtration rate (eGFR), urine albumin:creatinine ratio (ACR), body mass index (BMI), smoking status, and foot examination. Retinal screening is additionally recommended and is often listed as a ninth process. These checks are designed to identify and address risk factors early, reducing the burden of preventable complications.

If your HbA1c has been recorded at 8.0% (64 mmol/mol) without a clear clinical rationale for that level, it is advisable to discuss this with your GP or diabetes nurse to ensure your care plan is appropriately aligned with current NICE NG28 recommendations.

Key references: NICE NG28 (Type 2 diabetes in adults: management); NHS England/National Diabetes Audit — The Eight Care Processes.

How Occupational Health and Private Medical Assessments Use HbA1c

Occupational health providers and private medical assessors, including Passport Health Plan, may flag an HbA1c of 8.0% as suboptimal, but decisions are made case by case and are not governed by NHS or NICE rules.

Occupational health providers, private medical insurers, and travel health services may use HbA1c as a key metric to assess how well diabetes is controlled. This is because HbA1c provides an objective, standardised measure of glycaemic management that is reproducible and widely understood across clinical settings.

In the context of health assessments or medical screenings, an HbA1c of 8.0% may be flagged as indicating suboptimal control. Depending on the purpose of the assessment — for example, fitness-to-work evaluations, insurance underwriting, or pre-employment medicals — this result could influence recommendations around further investigation, treatment review, or monitoring frequency. It is important to note that underwriting and occupational health decisions vary considerably between providers and are not set by the NHS or NICE; they are made on a case-by-case basis by the relevant provider.

There is no universal rule linking a specific HbA1c value to automatic exclusion from coverage or clearance. Decisions typically take into account the full clinical picture. Demonstrating active engagement with diabetes management — including regular GP reviews, medication adherence, and lifestyle modifications — can support a more favourable assessment outcome.

If you are undergoing an occupational health or private medical assessment and your HbA1c has been recorded at 8.0%, it may be helpful to:

• Bring documentation of your most recent diabetes review

• Provide a list of current medications and any recent changes

• Highlight any lifestyle changes you have made to improve control

• Ask your GP for a supporting letter if required by the provider

Regardless of any private or occupational health assessment, your NHS GP should remain the central point of coordination for your diabetes care.

Steps to Lower Your HbA1c: Lifestyle, Medication and Monitoring

Reducing HbA1c from 8.0% involves dietary changes, at least 150 minutes of weekly moderate exercise, weight management, smoking cessation, and medication review in line with NICE NG28.

Reducing an HbA1c from 8.0% to a lower, more optimal level is achievable for many people through a combination of lifestyle changes, medication optimisation, and appropriate monitoring. The approach should be gradual and sustainable. People taking insulin or sulphonylureas should be aware of the risk of hypoglycaemia if glucose levels fall quickly; in rare cases, a rapid improvement in long-standing poor control has also been associated with early worsening of diabetic retinopathy, though this is uncommon. Your diabetes team can advise on a safe rate of improvement for your individual circumstances.

Lifestyle modifications remain the cornerstone of diabetes management:

• Dietary changes: Reducing refined carbohydrates, sugary drinks, and processed foods whilst increasing fibre, vegetables, and lean protein can meaningfully lower blood glucose levels. A referral to a registered dietitian may be beneficial.

• Physical activity: Regular aerobic exercise — at least 150 minutes per week of moderate-intensity activity, in line with the UK Chief Medical Officers' Physical Activity Guidelines — improves insulin sensitivity and helps lower HbA1c.

• Weight management: Even modest weight loss of 5–10% of body weight can significantly improve glycaemic control in people with type 2 diabetes. NHS Better Health offers free weight management support.

• Smoking cessation: Smoking worsens insulin resistance and cardiovascular risk. NHS Stop Smoking services are freely available and have a strong evidence base.

Medication review is equally important. Metformin remains the recommended first-line pharmacological treatment for type 2 diabetes in most adults, if tolerated (NICE NG28). If lifestyle changes and first-line medication are insufficient, your GP may consider intensifying treatment in line with NICE NG28 and relevant NICE technology appraisals. For example, SGLT-2 inhibitors (such as empagliflozin or dapagliflozin) or GLP-1 receptor agonists may be considered in specific clinical contexts — for instance, where established cardiovascular disease or chronic kidney disease is present, or where BMI and other criteria are met. Your prescriber will take into account your full clinical picture when selecting the most appropriate option.

If you experience any suspected side effects from your diabetes medication, you can report these directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Self-monitoring of blood glucose (SMBG) is not routinely recommended for adults with type 2 diabetes who are not on insulin, unless specific clinical indications apply (NICE NG28). Where SMBG is appropriate, your diabetes team will advise on frequency and targets. Access to flash glucose monitoring or continuous glucose monitoring (CGM) devices is available on the NHS for people with type 2 diabetes who meet defined NICE criteria — your diabetes team can advise whether you are eligible.

Key references: NICE NG28; UK Chief Medical Officers' Physical Activity Guidelines; NHS Better Health; NHS Stop Smoking services; MHRA Yellow Card scheme.

Working With Your GP or Diabetes Team to Review Your Care

An HbA1c of 8.0% should prompt a structured annual diabetes review with your GP or diabetes nurse, covering all eight NHS care processes including blood pressure, cholesterol, kidney function, BMI, and foot examination.

Effective diabetes management is a collaborative process. If your HbA1c is recorded at 8.0%, this is an important prompt to arrange a structured review with your GP, practice nurse, or diabetes specialist nurse. In England, people with type 2 diabetes are entitled to an annual diabetes review through their GP surgery. This should include all eight NHS care processes: HbA1c measurement, blood pressure, serum cholesterol, serum creatinine and eGFR, urine albumin:creatinine ratio (ACR), BMI, smoking status, and foot examination. Retinal screening should also be arranged separately if not already up to date.

During your review, it is helpful to come prepared. Consider keeping a record of:

• Blood glucose readings (if you self-monitor) over the preceding weeks

• Any recent changes in diet, activity levels, or stress

• Medication side effects or difficulties with adherence

• Symptoms that may suggest hypoglycaemia or hyperglycaemia

Your GP or diabetes team can use this information to make informed, shared decisions about whether to adjust your medication, refer you to a specialist service, or enrol you in a structured education programme. NHS-funded options include DESMOND (Diabetes Education and Self Management for Ongoing and Newly Diagnosed) and X-PERT Diabetes, among others, depending on local availability through your Integrated Care Board (ICB).

If your diabetes is also reviewed through an occupational health or private medical service, it is important to ensure that your NHS GP remains the central point of coordination for your care. Private or occupational health assessments can complement NHS care but should not replace it. Keeping your GP informed of any recommendations made through other channels ensures continuity and safety.

Key references: NHS England/National Diabetes Audit — The Eight Care Processes; NICE NG28.

When to Seek Further Assessment or Specialist Referral

Seek emergency care for symptoms of DKA or HHS; contact your GP promptly for persistent hyperglycaemia, recurrent hypoglycaemia, or foot problems; specialist referral is appropriate if HbA1c remains above target despite optimised treatment.

Whilst an HbA1c of 8.0% does not in itself constitute a medical emergency, there are circumstances in which prompt further assessment or specialist referral is warranted. Knowing when to escalate is an important aspect of safe diabetes self-management.

Seek emergency care (call 999 or go to A&E) if you experience symptoms that may suggest diabetic ketoacidosis (DKA) or hyperosmolar hyperglycaemic state (HHS), including:

• Severe thirst, nausea, vomiting, or abdominal pain

• Confusion, drowsiness, or difficulty staying awake

• Rapid or laboured breathing

• Breath that smells fruity or of acetone

• High blood ketone readings (if you have a ketone meter)

For urgent but non-emergency concerns, contact NHS 111 for advice.

Contact your GP promptly if you experience:

• Persistent symptoms of high blood glucose, such as excessive thirst, frequent urination, fatigue, or blurred vision

• Recurrent episodes of hypoglycaemia, particularly if severe or occurring without warning

• Unexplained weight loss

• Foot problems, including ulcers, wounds that are slow to heal, redness, swelling, or warmth — these require urgent assessment and should not be left untreated. An acutely infected or ischaemic foot should be referred urgently to the local foot protection team or equivalent service, in line with NICE NG19

• Chest pain, breathlessness, or other symptoms that may indicate cardiovascular complications

Specialist referral to a diabetes consultant or multidisciplinary diabetes team may be appropriate if:

• HbA1c remains persistently above target despite optimised lifestyle and medication

• There is diagnostic uncertainty (for example, possible latent autoimmune diabetes in adults, known as LADA)

• Complex medication regimens, including insulin initiation or intensification, are being considered

• Significant comorbidities such as chronic kidney disease or heart failure are present

In the UK, referrals to secondary care diabetes services are made through your GP and are guided by local pathways set by your Integrated Care Board (ICB). The MHRA provides up-to-date safety information on diabetes medications via the Yellow Card scheme (yellowcard.mhra.gov.uk), and your prescriber will take current guidance into account when reviewing your treatment. Proactive engagement with your healthcare team remains the most effective strategy for achieving and maintaining good glycaemic control.

Key references: NICE NG28; NICE NG19 (Diabetic foot problems: prevention and management); NHS 111; MHRA Yellow Card scheme.

Frequently Asked Questions